Drug Developement/Delivery
- Advances in TROP-2 Directed ADCs
- Development of PD-L1 Antibody Drug Conjugates (ADC)
- Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
- Maytansinoids as Payloads of ADCs: DM1, DM4
- Antibody-drug Conjugates for HER2-Positive Gastric Cancer
- c-MET: A Novel Target for Anticancer Therapies
- Nectin-4-Directed Drugs for Solid Tumors
- Claudin18.2 Targeted Therapies In Cancer
- FDA Approves Tivdak - First Tissue Factor (TF)-Targeted Antibody Conjugate Drug (ADC)
- ADC Drugs Global Sales of 2021 and Future Prospects